Real-World: Mid-Market Biotech Scales Pharmacovigilance Signals with Databricks and Agentic AI

Real-World: Mid-Market Biotech Scales Pharmacovigilance Signals with Databricks and Agentic AI

1. Problem / Context

A phase II biotech (~$120M revenue) with a lean pharmacovigilance (PV) function faces the classic mid-market challenge: meeting FDA/EMA expectations for safety monitoring without an army of case processors or data engineers. The workload spans literature surveillance, a crowded safety inbox, and real-world evidence (RWE) derived from de-identified EHR feeds. Each source produces potential individual case safety reports (ICSRs) that must be deduplicated, coded, narrated, and escalated when signals emerge—all under GxP validation expectations and tight timelines.

Manual triage and static rules struggle with the variability of unstructured language in case narratives, literature abstracts, and clinician notes. Duplicate detection is inconsistent, MedDRA coding is error-prone, and drafting narratives is time-consuming. Meanwhile, submission accuracy and audit readiness are non-negotiable. The company needs a governed, scalable way to detect signals earlier and process ICSRs faster—without growing headcount or increasing regulatory risk.

2. Key Definitions & Concepts

• Pharmacovigilance signal detection: Identifying patterns indicating a possible causal relationship between a product and adverse events.
• ICSR triage: Intake, deduplication, coding (e.g., MedDRA), narrative creation, and routing for regulatory submission.
• MedDRA: The Medical Dictionary for Regulatory Activities used to code adverse events.
• Disproportionality analysis: Statistical methods (e.g., ROR, PRR) that highlight safety signals across aggregated cases.
• Agentic AI: Governed automations composed of AI “agents” that can perceive, reason, and act across systems—coordinating tasks like source monitoring, information extraction, clustering, drafting, and escalation, with human-in-the-loop oversight.
• Databricks foundation: A unified analytics platform where literature, inbox, and EHR data land in governed storage, models are tracked (e.g., with MLflow), and workflows are orchestrated with reproducibility and auditability.

Why not naive RPA? Static keyword rules and screen-scrapes break on unstructured text and changing formats. PV work needs language understanding, domain ontologies (MedDRA), and a governed machine learning lifecycle with validation packs and change control. Agentic AI on Databricks provides the adaptive understanding RPA lacks, while still honoring GxP expectations through traceable data, versioned models, and auditable workflows.

3. Why This Matters for Mid-Market Regulated Firms

Mid-market biotechs operate with lean teams, limited budgets, and heavy compliance burdens. Audit inquiries, submission deadlines, and inspection readiness require accuracy, explainability, and consistent SOP adherence. Talent constraints make it hard to scale case volumes across literature and RWE sources. A governed agentic approach enables scale without proportionate headcount growth, turns fragmented tools into a coherent, auditable workflow, and keeps QA/Regulatory confident that validation and change control are intact.

4. Practical Implementation Steps / Roadmap

1. Ingest and standardize sources on Databricks

   • Connect literature feeds and indexing services; ingest safety inbox via secure connectors; land de-identified EHR RWE extracts.
   • Normalize to structured Delta tables with lineage. Track source provenance and timestamps for audit.

2. Foundation models and ontologies

   • Use domain-tuned NLP to extract entities (drug, event, patient info), map to MedDRA preferred terms, and identify potential seriousness criteria.
   • Maintain MedDRA versioning and mappings in governed tables for reproducibility.

3. Agentic triage and deduplication

   • Agents monitor incoming records, apply fuzzy matching and clustering to detect potential duplicates, and attach confidence scores.
   • Cluster cases by drug-event pair, reporter, and temporal proximity to surface suspected duplicates before coding.

4. Narrative drafting and coding assistance

   • An agent drafts case narratives from structured fields and extracted text, citing source snippets.
   • Safety specialists review, correct, and approve; edits are stored for supervised model improvement via MLflow experiments.

5. Signal screening

   • Compute disproportionality metrics and trend lines by product, population, and geography.
   • Agents flag candidate signals to safety leads with rationale, confidence, and links to supporting cases.

6. Human-in-the-loop and workflow orchestration

   • A governed queue routes cases to safety reviewers based on role and workload.
   • Approvals, rejections, and escalations generate immutable audit logs.
   • Packaging for submission uses validated templates.

7. Operate under GxP-aligned controls

   • Validation packs verify data pipelines, model performance thresholds, and workflow behavior.
   • MLflow tracks model versions, training data signatures, metrics, and deployment approvals.

Kriv AI, as a governed AI and agentic automation partner, often supports these steps by stitching together data readiness, MLOps, and workflow orchestration so lean PV teams can adopt AI safely without rebuilding the stack from scratch.

5. Governance, Compliance & Risk Controls Needed

• GxP-aligned validation plan: Define intended use, risk classification, acceptance criteria, and traceability from requirements to test evidence. Bundle pipeline, model, and workflow tests into a reusable validation package.
• Change control: Version data schemas, MedDRA dictionaries, models, and prompts. Require role-based approvals for deployment; capture rationale and impact assessment.
• MLflow-tracked models: Record model lineage, datasets, metrics, and signatures to support periodic revalidation and inspection requests.
• Role-based access and segregation of duties: Ensure reviewers, approvers, and administrators have appropriate, distinct permissions; enforce least privilege.
• Audit trails: Immutable logs for data ingress, model inferences, reviewer edits, and submissions. Provide time-stamped history suitable for FDA/EMA inspection.
• Data protection: Keep PHI de-identified when feasible; apply encryption, masking, and regional residency controls.
• Cross-functional SOP ownership: Safety, Clinical Ops, and QA/Regulatory co-own SOPs for triage, coding, validation, and change management to maintain alignment.

Kriv AI’s governance-first approach helps mid-market teams operationalize these controls on Databricks without slowing delivery, providing templates for validation evidence, approval workflows, and audit reporting.

6. ROI & Metrics

Measuring impact requires baselines and ongoing telemetry:

• Case processing time: Reduced by 35% through automated extraction, deduplication, and narrative drafts. Track median minutes per ICSR pre/post.
• Duplicate rate: Down 50% due to clustering and fuzzy matching that surface suspected duplicates earlier. Monitor duplicate confirmations per 100 cases.
• Submission error rate: Down 30%, driven by consistent MedDRA mapping and validated submission templates. Track corrections requested by authorities.
• Backlog and cycle time: Monitor queue lengths and time-to-review for safety leads.
• Labor savings and payback: Combine cycle-time reduction with case volumes to estimate hours saved. For a lean PV team, savings often offset platform and validation costs within a few quarters, while improving inspection readiness.

7. Common Pitfalls & How to Avoid Them

• Pilot-graveyard from validation burden: Teams pilot well but stall at go-live. Counter with a GxP-aligned validation plan from day one, automated test evidence capture, and role-based deployment approvals.
• Naive RPA and keyword rules: These miss context and degrade quickly. Use agentic NLP with MedDRA grounding and continuous monitoring of model drift.
• Unmanaged MedDRA updates: Version dictionary changes and re-validate mapping logic to prevent silent errors.
• Weak deduplication: Over- or under-merging cases can corrupt signal analysis. Use multi-signal matching (entities, time, reporter, narrative similarity) and require human verification for low-confidence merges.
• Data quality gaps: Apply schema checks, PII scans, and completeness thresholds at ingestion; block downstream steps when quality gates fail.
• Siloed ownership: PV, Clinical Ops, and QA/Regulatory must co-own SOPs and change control; schedule joint reviews to prevent misalignment.

30/60/90-Day Start Plan

First 30 Days

• Discovery: Inventory literature sources, safety inbox formats, and EHR RWE feeds; document current triage SOPs and acceptance criteria.
• Data checks: Land sample datasets on Databricks; profile quality, PII/PHI risk, and MedDRA mapping coverage.
• Governance boundaries: Draft intended-use statement, validation approach, and role definitions (reviewer, approver, admin). Set up MLflow and audit logging.

Days 31–60

• Pilot workflows: Implement ingestion to Delta tables, agentic deduplication and MedDRA extraction, and narrative drafting for a limited product/signal scope.
• Orchestration and security: Stand up queues, role-based routing, and approval steps. Enforce least-privilege access and audit trails.
• Evaluation: Compare pilot vs. baseline on cycle time, duplicate detection accuracy, and submission quality. Capture validation evidence continuously.

Days 61–90

• Scaling: Expand to additional products and sources; schedule MedDRA updates and model retraining cadence.
• Monitoring: Add drift detection, data quality gates, and SLA dashboards for reviewers.
• Stakeholder alignment: Finalize SOP updates with Safety, Clinical Ops, and QA/Regulatory; complete change control and move to controlled production.

9. Industry-Specific Considerations

• Global oversight: Harmonize evidence and submissions for FDA and EMA expectations; align on seriousness criteria and timelines.
• EHR-derived RWE: Ensure de-identification, provenance tracking, and bias checks across sites and geographies.
• Literature variability: Handle multilingual abstracts and publisher format changes through resilient ingestion and language models.

10. Conclusion / Next Steps

A governed agentic AI approach on Databricks lets a lean, phase II biotech scale PV signal detection and ICSR triage without compromising GxP expectations. By combining data readiness, MedDRA-aware NLP, deduplication, and human-in-the-loop review with validation and auditability, teams improve speed, quality, and inspection readiness.

If you’re exploring governed Agentic AI for your mid-market organization, Kriv AI can serve as your operational and governance backbone. With a focus on data readiness, MLOps, and workflow orchestration for regulated teams, Kriv AI helps turn pilots into reliable, ROI-positive PV operations.